SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.24
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$21.62

02 Oct
2025

0.300

OPEN

$21.55

1.41%

HIGH

$21.71

1,655,011

LOW

$21.37

TARGET
$27.455 27.0% upside
Franking for last dividend paid out: 35%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MDR . MPL . MVF . NHF . PSQ . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 107.0 120.5 xxx
DPS (cps) xxx 107.0 106.0 xxx
EPS Growth xxx - 0.4% 12.7% xxx
DPS Growth xxx 0.9% - 1.0% xxx
PE Ratio xxx N/A 17.9 xxx
Dividend Yield xxx N/A 4.9% xxx
Div Pay Ratio(%) xxx 100.0% 87.9% xxx

Dividend yield today if purchased 3 years ago: 3.41%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 4.95

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx107.0
DPS All xxxxxxxxxxxxxxx107.0
Sales/Revenue xxxxxxxxxxxxxxx9,489.5 M
Book Value Per Share xxxxxxxxxxxxxxx1,733.3
Net Operating Cash Flow xxxxxxxxxxxxxxx1,296.8 M
Net Profit Margin xxxxxxxxxxxxxxx5.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx6.32 %
Return on Invested Capital xxxxxxxxxxxxxxx4.14 %
Return on Assets xxxxxxxxxxxxxxx3.21 %
Return on Equity xxxxxxxxxxxxxxx6.32 %
Return on Total Capital xxxxxxxxxxxxxxx5.95 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx446.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx461 M
Long Term Debt xxxxxxxxxxxxxxx4,710 M
Total Debt xxxxxxxxxxxxxxx5,171 M
Goodwill - Gross xxxxxxxxxxxxxxx9,315 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx674 M
Price To Book Value xxxxxxxxxxxxxxx1.55

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx462.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.88 %
Cost of Goods Sold xxxxxxxxxxxxxxx7,072 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,637 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx231 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

22/08/2025

1

Buy

$29.33

35.66%

Morgans states Sonic Healthcare reported a “weak” FY25 result, which met guidance, though net profit after tax was impacted by higher costs, including D&A, interest, and tax.

Normalised earnings (EBITDA) margins rose 40bps to 18.1% on 5% organic revenue growth and cost reductions. Organic revenue growth slowed from 6.1% in 1H25 across most regions and appears country-specific rather than structural.

Radiology grew 10%, with 2H25 up 8%. Margin lifted 45bps to 24.8%, benefiting from Medicare fee indexation of 3.5% from July 1, 2024.

Morgans lowers its net profit forecasts by -8.1% on higher D&A, net interest expenses, and tax.

No change in Buy rating. Target falls to $29.33 from $31.36.

FORECAST
Morgans forecasts a full year FY26 dividend of 109.00 cents and EPS of 128.00 cents.
Morgans forecasts a full year FY27 dividend of 111.00 cents and EPS of 143.00 cents.

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

26/08/2025

3

Neutral

$27.92

29.14%

Jarden notes Sonic Healthcare's FY25 adjusted EBITDA missed the consensus by -2%, and net profit missed consensus by -3.8% and the broker's forecast by -2%.

The drivers of weakness included Cyclone Alfred impact in Australia in 2H, US impacted by West Division sale, payor loss and cyber disruption, and Germany hit by KV quota cuts.

FY26 EBITDA guidance was slightly weaker than expected, and at the net profit line was -8% below the broker's forecast on incremental D&A, interest and tax.

The broker trimmed FY26 EBITDA forecast by -1.5% and FY27 by -1.3%, with deeper cuts to net profit forecasts.

Neutral. Target cut to $27.92 from $29.84.

FORECAST
Jarden forecasts a full year FY26 dividend of 97.00 cents and EPS of 121.50 cents.
Jarden forecasts a full year FY27 dividend of 108.70 cents and EPS of 149.20 cents.
Access Extra Coverage Research History >

SHL STOCK CHART

FNArena News on SHL

Latest Healthcare services News

1
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
2
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
3
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
4
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
5
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
6
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
7
Healius Enjoying Testing Times

Dec 11 2020 - Australia
8
The First Connection

Dec 10 2020 - Weekly Reports
9
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
10
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia